NPCE

NeuroPace, Inc. [NPCE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

NPCE Stock Summary

In the News

07:42 29 May 2023 NPCE

NeuroPace, Inc. (NPCE) CEO Michael Favet on Q1 2023 Results - Earnings Call Transcript

NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group Michael Favet - President & Chief Executive Officer, NeuroPace, Inc. Rebecca Kuhn - Chief Financial Officer & Vice President, NeuroPace, Inc. Conference Call Participants Rohan - JP Morgan Frank Takkinen - Lake Street Capital Markets Michael Polark - Wolfe Research Operator Good afternoon, and welcome to NeuroPace's First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

04:05 29 May 2023 NPCE

NeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023

MOUNTAIN VIEW, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2023 after market close on Thursday, May 4, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

04:05 29 May 2023 NPCE

NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare Conference

MOUNTAIN VIEW, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 22nd Annual Needham Virtual Healthcare Conference.

10:21 29 May 2023 NPCE

NeuroPace, Inc. (NPCE) Q4 2022 Earnings Call Transcript

NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2022 Results Conference Call March 2, 2023 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group Michael Favet - President, CEO & Director Rebecca Kuhn - CFO, VP, Finance & Administration and Assistant Secretary Conference Call Participants Michael Polark - Wolfe Research Frank Takkinen - Lake Street Capital Markets Robbie Marcus - JPMorgan Vik Chopra - Wells Fargo Drew Ranieri - Morgan Stanley Operator Good afternoon, and welcome to NeuroPace's Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

08:00 29 May 2023 NPCE

NeuroPace to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

MOUNTAIN VIEW, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2022 after market close on Thursday, March 2, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

04:03 29 May 2023 NPCE

NeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.

01:35 29 May 2023 NPCE

Accelmed Partners Takes Activist Position in NPCE / Neuropace After Q3 Results

Fintel reports that Accelmed Partners II L.P.

08:55 29 May 2023 NPCE

Neuropace, Inc. (NPCE) Q3 2022 Earnings Call Transcript

Neuropace, Inc. (NASDAQ:NPCE ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group Michael Favet - President, CEO & Director Rebecca Kuhn - CFO, VP, Finance & Administration and Assistant Secretary Conference Call Participants Allen Gong - JPMorgan Chase & Co. Lawrence Biegelsen - Wells Fargo Securities Operator Good day, and thank you for standing by. Welcome to the Q3 2022 NeuroPace earnings conference call.

04:03 29 May 2023 NPCE

NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 4th Annual Wolfe Research Healthcare Conference. Management is scheduled to present on Wednesday, November 16th at 2:40 p.m. Eastern Time. A live webcast of this event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://investors.neuropace.com. The webcasts will be archived and available for replay for at least 90 days after the event.

04:03 29 May 2023 NPCE

NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022

MOUNTAIN VIEW, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter 2022 after market close on Tuesday, November 8, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.

NPCE Financial details

Company Rating
Buy
Market Cap
114.32M
Income
-54.61M
Revenue
48.62M
Book val./share
1.1
Cash/share
2.69
Dividend
-
Dividend %
-
Employees
163
Optionable
No
Shortable
Yes
Earnings
09 Aug 2023
P/E
-2.07
Forward P/E
-
PEG
0.84
P/S
2.35
P/B
4.11
P/C
1.64
P/FCF
-3.21
Quick Ratio
7.78
Current Ratio
9.13
Debt / Equity
2.87
LT Debt / Equity
2.51
-
-
EPS (TTM)
-2.2
EPS next Y
-
EPS next Q
-
EPS this Y
-25.68%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
13.16%
EPS Q/Q
14%
-
-
-
-
SMA20
-20%
SMA50
-
SMA100
300%
Inst Own
71.85%
Inst Trans
1.66%
ROA
-51%
ROE
-138%
ROC
-0.41%
Gross Margin
71%
Oper. Margin
-81%
Profit Margin
-112%
Payout
-
Shs Outstand
25.41M
Shs Float
6.87M
-
-
-
-
Target Price
5.5
52W Range
1.22-6.5
52W High
-26.33%
52W Low
+342%
RSI
49
Rel Volume
0.31
Avg Volume
22.19K
Volume
6.95K
Perf Week
4.25%
Perf Month
-7.14%
Perf Quarter
179.75%
Perf Half Y
194.67%
-
-
-
-
Beta
2.54331
-
-
Volatility
0.07%, 0.28%
Prev Close
-1.78%
Price
4.42
Change
-3.91%

NPCE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
3.333.712.721.85
Net income per share
-3.41-3.2-2.92-2.17
Operating cash flow per share
-2.25-1.95-1.48-1.5
Free cash flow per share
-2.3-1.95-1.5-1.52
Cash per share
0.463.436.963.15
Book value per share
-11.65-13.314.431.41
Tangible book value per share
-11.65-13.314.431.41
Share holders equity per share
-11.65-13.314.431.41
Interest debt per share
6.515.83.453.14
Market cap
277.14M277.14M167.42M36.65M
Enterprise value
335.82M303.61M198.08M99.81M
P/E ratio
-7.31-7.81-3.46-0.69
Price to sales ratio
7.56.743.710.81
POCF ratio
-11.07-12.83-6.81-0.99
PFCF ratio
-10.87-12.79-6.71-0.98
P/B Ratio
-2.14-1.872.281.05
PTB ratio
-2.14-1.872.281.05
EV to sales
9.087.384.382.19
Enterprise value over EBITDA
-16.73-24.33-6.98-2.52
EV to operating cash flow
-13.42-14.05-8.06-2.71
EV to free cash flow
-13.17-14.01-7.94-2.66
Earnings yield
-0.14-0.13-0.29-1.46
Free cash flow yield
-0.09-0.08-0.15-1.02
Debt to equity
-1.16-1.380.822.28
Debt to assets
7.133.640.450.7
Net debt to EBITDA
-2.92-2.12-1.08-1.6
Current ratio
0.275.6914.288.9
Interest coverage
-2.32-1.14-3.2-5.42
Income quality
0.830.890.680.78
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
0.490.380.40.48
Intangibles to total assets
0000
Capex to operating cash flow
0.0200.020.02
Capex to revenue
-0.010-0.01-0.01
Capex to depreciation
-1.11-0.2-1.3-0.2
Stock based compensation to revenue
0.040.030.090.18
Graham number
29.9230.9517.048.31
ROIC
-2.33-8.59-0.34-0.47
Return on tangible assets
-1.8-0.63-0.36-0.47
Graham Net
-12.33-14.053.90.35
Working capital
-54.89M44.97M123.52M86.74M
Tangible asset value
-129.35M-147.83M73.5M34.78M
Net current asset value
-130.19M-149.22M72.76M18.39M
Invested capital
-0.49-0.360.682.01
Average receivables
07.21M7.74M7.29M
Average payables
0926K1.16M1.76M
Average inventory
07.4M7.37M8.77M
Days sales outstanding
59.474.4957.2859.99
Days payables outstanding
31.3731.8842.8160.16
Days of inventory on hand
274.41232.08243.02272.12
Receivables turnover
6.144.96.376.08
Payables turnover
11.6411.458.536.07
Inventory turnover
1.331.571.51.34
ROE
0.290.24-0.66-1.53
Capex per share
-0.04-0.01-0.02-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric History 2022-03-312022-06-302022-09-302022-12-31 2023-03-31
Revenue per share
0.470.420.450.510.58
Net income per share
-0.54-0.59-0.54-0.5-0.57
Operating cash flow per share
-0.47-0.43-0.28-0.32-0.39
Free cash flow per share
-0.48-0.44-0.28-0.32-0.39
Cash per share
4.243.773.453.122.69
Book value per share
2.582.161.761.41.1
Tangible book value per share
2.582.161.761.41.1
Share holders equity per share
2.582.161.761.41.1
Interest debt per share
2.422.412.842.892.88
Market cap
199.56M121.29M92.73M37M116.45M
Enterprise value
249.05M172.77M155.38M100.16M180.1M
P/E ratio
-3.79-2.1-1.73-0.74-2.02
Price to sales ratio
17.5511.898.312.898.05
POCF ratio
-17.52-11.38-13.3-4.72-12.01
PFCF ratio
-17.06-11.21-13.24-4.66-11.85
P/B Ratio
3.182.292.141.064.24
PTB ratio
3.182.292.141.064.24
EV to sales
21.916.9413.937.8312.44
Enterprise value over EBITDA
-28.05-17.12-17-10.88-22.47
EV to operating cash flow
-21.86-16.21-22.28-12.77-18.57
EV to free cash flow
-21.29-15.96-22.18-12.61-18.32
Earnings yield
-0.07-0.12-0.14-0.34-0.12
Free cash flow yield
-0.06-0.09-0.08-0.21-0.08
Debt to equity
1.051.241.782.282.87
Debt to assets
0.510.550.640.70.74
Net debt to EBITDA
-5.57-5.1-6.85-6.86-7.94
Current ratio
10.159.8611.088.99.13
Interest coverage
-5.33-5.93-5.35-5.08-4.23
Income quality
0.990.840.590.70.93
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.490.560.50.40.36
Intangibles to total assets
00000
Capex to operating cash flow
0.030.0200.010.01
Capex to revenue
-0.03-0.020-0.01-0.01
Capex to depreciation
-0.41-0.22-0.04-0.14-0.33
Stock based compensation to revenue
0.130.260.20.160.15
Graham number
5.615.344.623.973.76
ROIC
-0.1-0.12-0.11-0.11-0.13
Return on tangible assets
-0.1-0.12-0.11-0.11-0.14
Graham Net
1.971.520.750.340.04
Working capital
110.36M101.06M94.95M86.74M80.28M
Tangible asset value
62.82M52.9M43.41M34.78M27.49M
Net current asset value
56.26M46.82M27.31M18.39M11.38M
Invested capital
0.911.081.572.012.56
Average receivables
8.08M8.77M8.18M7.68M8.34M
Average payables
1.11M1.87M1.34M1.66M1.99M
Average inventory
7.96M8.26M8.5M9.15M10.23M
Days sales outstanding
71.774.7763.5352.6557.18
Days payables outstanding
64.3749.4833.1348.4840.15
Days of inventory on hand
234.12277.14241.95219.29235.98
Receivables turnover
1.261.21.421.711.57
Payables turnover
1.41.822.721.862.24
Inventory turnover
0.380.320.370.410.38
ROE
-0.21-0.27-0.31-0.36-0.52
Capex per share
-0.01-0.0100-0.01

NPCE Frequently Asked Questions

What is NeuroPace, Inc. stock symbol ?

NeuroPace, Inc. is a US stock , located in Mountain view of Ca and trading under the symbol NPCE

Is NeuroPace, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $5.75. The lowest prediction is $5.5 and the highest is $6

What is NPCE stock prediction ?

What is NeuroPace, Inc. stock quote today ?

NeuroPace, Inc. stock price is $4.42 today.

Is NeuroPace, Inc. stock public?

Yes, NeuroPace, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Same Price Range
Similar Market Cap